MX2023008738A - Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático. - Google Patents
Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático.Info
- Publication number
- MX2023008738A MX2023008738A MX2023008738A MX2023008738A MX2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A MX 2023008738 A MX2023008738 A MX 2023008738A
- Authority
- MX
- Mexico
- Prior art keywords
- neuropathic pain
- focal epilepsy
- adeno
- associated virus
- ion channels
- Prior art date
Links
- 206010061334 Partial seizures Diseases 0.000 title abstract 4
- 201000007186 focal epilepsy Diseases 0.000 title abstract 4
- 208000004296 neuralgia Diseases 0.000 title abstract 4
- 208000021722 neuropathic pain Diseases 0.000 title abstract 4
- 210000000234 capsid Anatomy 0.000 title abstract 3
- 241000702421 Dependoparvovirus Species 0.000 title 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 title 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 title 1
- 210000002569 neuron Anatomy 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000013607 AAV vector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 230000010415 tropism Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente descripción proporciona composiciones y métodos para el tratamiento contra el dolor neuropático o la epilepsia focal. Además, se proporcionan polipéptidos y/o ácidos nucleicos de la cápside de AAV adecuados para transducir neuronas relacionadas con el dolor neuropático o la epilepsia focal. La descripción se refiere a vectores de AAV que comprenden específicos polipéptidos de la cápside que proporcionan eficiencia de transducción y/o tropismo deseables para las neuronas responsables del dolor neuropático o el manejo de la epilepsia focal.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141121P | 2021-01-25 | 2021-01-25 | |
| US202163141124P | 2021-01-25 | 2021-01-25 | |
| US202163285929P | 2021-12-03 | 2021-12-03 | |
| PCT/US2022/013658 WO2022159871A1 (en) | 2021-01-25 | 2022-01-25 | Adeno-associated virus capsids and engineered ligand-gated ion channels for treating focal epilepsy and neuropathic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008738A true MX2023008738A (es) | 2023-09-12 |
Family
ID=82549286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008738A MX2023008738A (es) | 2021-01-25 | 2022-01-25 | Cápsides de virus adenoasociados y canales iónicos controlados por ligandos diseñados para el tratamiento contra epilepsia focal y dolor neuropático. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240108760A1 (es) |
| EP (1) | EP4281551A1 (es) |
| JP (1) | JP2024505197A (es) |
| KR (1) | KR20230149299A (es) |
| AU (1) | AU2022211055A1 (es) |
| CA (1) | CA3205877A1 (es) |
| IL (1) | IL304511A (es) |
| MX (1) | MX2023008738A (es) |
| WO (1) | WO2022159871A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102199626B (zh) * | 2003-09-30 | 2015-06-24 | 宾夕法尼亚大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| KR20200108514A (ko) * | 2015-09-17 | 2020-09-21 | 코다 바이오테라퓨틱스 인코포레이티드 | 신경 장애를 치료하기 위한 조성물 및 방법 |
| MX2020005470A (es) * | 2017-11-27 | 2020-11-09 | Coda Biotherapeutics Inc | Composiciones y metodos para enfermedades neurologicas. |
-
2022
- 2022-01-25 AU AU2022211055A patent/AU2022211055A1/en active Pending
- 2022-01-25 JP JP2023544528A patent/JP2024505197A/ja active Pending
- 2022-01-25 EP EP22743368.7A patent/EP4281551A1/en active Pending
- 2022-01-25 KR KR1020237028925A patent/KR20230149299A/ko unknown
- 2022-01-25 MX MX2023008738A patent/MX2023008738A/es unknown
- 2022-01-25 CA CA3205877A patent/CA3205877A1/en active Pending
- 2022-01-25 US US18/273,867 patent/US20240108760A1/en active Pending
- 2022-01-25 WO PCT/US2022/013658 patent/WO2022159871A1/en active Application Filing
-
2023
- 2023-07-17 IL IL304511A patent/IL304511A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240108760A1 (en) | 2024-04-04 |
| AU2022211055A1 (en) | 2023-08-17 |
| IL304511A (en) | 2023-09-01 |
| JP2024505197A (ja) | 2024-02-05 |
| AU2022211055A9 (en) | 2024-07-11 |
| WO2022159871A1 (en) | 2022-07-28 |
| EP4281551A1 (en) | 2023-11-29 |
| KR20230149299A (ko) | 2023-10-26 |
| CA3205877A1 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792236A1 (ru) | Получение увеличенных в размере векторов на основе аденоассоциированного вируса | |
| WO2018204803A8 (en) | Compositions and methods of treating huntington's disease | |
| PH12020551938A1 (en) | Liver targeting adeno-associated viral vectors | |
| TN2020000187A1 (en) | Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism | |
| JP2020508648A5 (es) | ||
| EA202190512A1 (ru) | Композиции и способы для производства векторов для генной терапии | |
| WO2019241535A3 (en) | Anion exchange chromatography for recombinant aav production | |
| WO2017066764A3 (en) | Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses | |
| WO2021018859A3 (en) | Antibodies binding to gprc5d | |
| EP4269579A3 (en) | Gene therapy constructs for treating wilson disease | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| PH12021551155A1 (en) | Recombinant viral vectors and nucleic acids for producing the same | |
| MX2018007234A (es) | Vectores virales adenoasociados utiles en el tratamiento de atrofia muscular espinal. | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| WO2012145509A3 (en) | Adeno-associated-virus rep sequences, vectors, and viruses | |
| MX2022012855A (es) | Virus adenoasociado con cápside modificada geneticamente. | |
| WO2013173512A3 (en) | High-transduction-efficiency raav vectors, compositions, and methods of use | |
| WO2015081101A8 (en) | Adeno-associated virus vectors for treatment of glycogen storage disease | |
| SG10201809075XA (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| MX353930B (es) | Composiciones y metodos para alterar la especificidad tisular y mejorar la transferencia de genes mediada por vector viral adeno-asociado 9. | |
| JOP20220043A1 (ar) | بروتين كابسيد vp1 معدل معزول من aav5 | |
| EP3947422A4 (en) | MANIPULATED ADENO-ASSOCIATED (AAV) VECTORS FOR TRANSGENE EXPRESSION | |
| EP3533877A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| AU2020299026A8 (en) | Methods and AAV vectors for in vivo transduction | |
| MX2020002809A (es) | Genes rep de aav inducibles. |